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To the Editor: Establishing reliable noninvasive 
methods for diagnosis of malaria has been a challenge. 
Lukianova-Helb et al. should be applauded for developing 
such a method on the basis of hemozoin (Hz) detection (1). 
The authors reported a proof of principle and are preparing 
for “large-scale studies in humans” (2). Such large endeav-
ors should be based on firm evidence, so it is surprising that 
the results presented were from a single patient, remarkable 
for the unusual quadruple drug treatment (2). In such a sce-
nario, to compensate for the limited data, the results should 
be of convincing scientific quality.
However, the case described raises several doubts that 
could have been addressed, such as the reliability of the di-
agnosis if only a thin film and a rapid test were used (co-in-
fection excluded) and why parasitemia was not determined 
at the time of the device test (instead of 4 hours before 
and 9 hours after). What developmental stages were the 
parasites in at the time of the evaluation (for example, al-
ready early trophozoites containing Hz or Hz-rich gameto-
cytes)? Why was the patient not re-evaluated to find out if 
repeated measurements would become appropriately nega-
tive (test-of-cure)?
The methods and results used in the study contrast 
with the extraordinary numbers for the limit of detection 
(LOD): 0.0001% in human blood and 0.00034% in a rodent 
model (1,2). However, the LOD is a virtual, inferred para-
sitemia rate based on the detection of free Hz added to un-
infected blood (1). An LOD can be obtained from serially 
diluted cultures or samples (3). In rodent models, detection 
of Hz tends to be much easier (4). Moreover, in Plasmodi-
um falciparum infections, only immature forms have been 
observed, with little or no detectable Hz (5).
The prospects of a noninvasive test for malaria are excit-
ing. However, in times of cost restraints, any diagnostic test 
or intervention should provide sufficiently convincing results 
before consideration of resource-intensive large-scale trials.
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From the Greek haima (“blood”) + zoon (“animal”), hemozoin is a pigment produced by malaria parasites from hemoglobin in the host’s red blood cells. This pigment was first 
observed by Johann Heinrich Meckel in 1847 in the blood and spleen of a mentally impaired 
person. In 1849, Rudolf Virchow made the connection to malaria, but it was initially believed 
that it was produced in the patient’s spleen as a part of the immune response to malaria. 
In 1880, Charles Louis Alphonse Laveran observed pigmented parasites in the blood of an 
Algerian soldier and realized that the parasites, not the patient, produce “malaria pigment.” 
The term “hemozoin” was coined by Louis Westenra Sambon.
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In Response: The letter by Rebelo et al. (1) that ques-
tions our previously described noninvasive malaria diag-
nostics (2,3) misinterprets both articles. The main objec-
tion comes to our alleged call for “large-scale studies in 
humans”; no such statement appeared in our 2014 article 
(2), and in the 2015 article (3), we clearly stated that large-
scale studies will be considered after the optimization of a 
new prototype and improving its sensitivity. The authors’ 
final questioning of our eligibility for resources is a nonsci-
entific opinion.
Concerning the quality of the standard clinical diagno-
sis, both thin blood film analysis and rapid diagnostic test 
results were obtained in a certified US clinical laboratory 
and returned consistent data. The lack of re-evaluation of 
the patient and the diagnostic timing are indeed limitations 
but were caused by the clinical restrictions. Our goal in the 
2015 article (3) was to demonstrate the first noninvasive 
diagnosis of malaria in a human, which was achieved. The 
additional parameters discussed in the letter were not the 
subject of this study. Their letter further misinterprets our 
2014 study, stating that parasitemia was virtual in that ar-
ticle; in fact, we studied actual infections among mice (2).
The criticism of Rebelo et al. might have been fueled 
by their own limited detection of hemozoin with flow cy-
tometry and microscopy (4), in which they used parasite 
cultures and an unspecified number of malaria patients. 
That the methods they used might not have performed well 
does not mean that the novel technology we described, 
based upon a different mechanism, would have the same 
limitations in detecting hemozoin.
In conclusion, we agree with the need for optimization 
of the technology and additional testing. We are currently 
developing and testing our technology in a malaria-endem-
ic country. Nevertheless, the letter by Rebelo et al. does not 
alter the fact that our novel noninvasive malaria diagnostic 
technology worked in a human.
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